Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis.
OBJECTIVE
To evaluate effects of zoledronate on markers of bone metabolism in dogs after transection of the cranial cruciate ligament (CrCL).


METHODS
21 adult dogs.


METHODS
Unilateral CrCL transection was performed arthroscopically. Dogs were allocated to 3 groups (control group, low-dose zoledronate [10 microg/kg, SC, q 90 d for 12 months], and high-dose zoledronate [25 microg/kg, SC, q 90 d for 12 months]). Serum osteocalcin (OC), serum bone-specific alkaline phosphatase (BAP), and urine pyridinoline and deoxypyridinoline concentrations were measured at 0, 1, 3, 6, 9, and 12 months after surgery. Bone mineral density (BMD) was determined in the distal portion of the femur and proximal portion of the tibia via computed tomography at each time point. Data were analyzed by a repeated-measures ANOVA.


RESULTS
oledronate inhibited OC in the high-dose group at 9 and 12 months and at 12 months in the low-dose group, compared with the control group. High-dose zoledronate decreased BAP concentrations 3 and 9 months after surgery. In the control group, BMD was decreased in the femoral condyle and caudal tibial plateau. Zoledronate prevented significant BMD decreases starting 1 month after transection, compared with control dogs. In the caudomedial aspect of the tibial plateau, both zoledronate groups had significant increases in BMD after 3 months, compared with control dogs.


CONCLUSIONS
Zoledronate may reduce subchondral bone loss and effect markers of bone metabolism in dogs with experimentally induced instability of the stifle joint and subsequent development of osteoarthritis.
Agnello
Kimberly A
KA
Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Trumble
Troy N
TN
Chambers
Jonathan N
JN
Seewald
Wolfgang
W
Budsberg
Steven C
SC
D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine; D000704:Analysis of Variance; D000818:Animals; D016118:Anterior Cruciate Ligament / Q000601:surgery*; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism*; D004164:Diphosphonates / Q000494:pharmacology*; D004283:Dog Diseases / Q000378:metabolism*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D007093:Imidazoles / Q000494:pharmacology*; D010003:Osteoarthritis / Q000378:metabolism / Q000662:veterinary*; D015675:Osteocalcin / Q000097:blood; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000662:veterinary; D000077211:Zoledronic Acid
D000596:Amino Acids; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D015675:Osteocalcin; C015484:pyridinoline; D000077211:Zoledronic Acid; D000469:Alkaline Phosphatase